Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 6/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3078974 | 1.00 | SLC1A3 (0.37) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 | |
| SCHEMBL3070733 | 0.75 | MET (0.39) | CYP2C19KMT2AMAOB | |
| SCHEMBL11590352 | 0.74 | SLC1A2 (0.53) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 | |
| SCHEMBL7792930 | 0.71 | IDO1 (0.44) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 | |
| SCHEMBL7977999 | 0.70 | SLC1A3 (0.60) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 | |
| SCHEMBL31103849 | 0.69 | SLC1A1 (0.48) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 | |
| SCHEMBL3077340 | 0.68 | PGD (0.31) | — | |
| SCHEMBL3080212 | 0.68 | PGD (0.31) | — | |
| SCHEMBL7347112 | 0.68 | PARP10 (0.40) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 | |
| SCHEMBL7789772 | 0.68 | MAOB (0.40) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790926-B2 | Alpha, omega-difunctional aldaramides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-7351862-B2 | Alpha, omega-difunctional aldaramides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| EP-1858955-A1 | PROCESSES USING ALPHA, OMEGA-DIFUNCTIONAL ALDARAMIDES AS MONOMERS AND CROSSLINKERS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1853554-A2 | ALPHA, OMEGA-DIFUNCTIONAL ALDARAMIDES | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2007-11-14 | — | — | EP | disclosed |
| US-20060258886-A1 | Alpha, omega-difuctional aldaramides | E. I. DU PONT DE NEMOURS AND COMPANY | 2006-11-16 | — | — | US | disclosed |
| WO-2006091902-A2 | ALPHA, OMEGA-DIFUNCTIONAL ALDARAMIDES | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006091901-A1 | PROCESSES USING ALPHA, OMEGA-DIFUNCTIONAL ALDARAMIDES AS MONOMERS AND CROSSLINKERS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258886-A1 | Alpha, omega-difuctional aldaramides | FADS2, FASN, DEGS1 | SLC1A3 1489/4885SLC1A2 1438/4885SLC1A1 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.